

Abstract

The present invention provides integrin-immunoglobulin chimeric protein heterodimer complexes in which the α chain and the β chain of an integrin are stably associated. The obtained integrin-immunoglobulin chimeric protein heterodimer complexes can be directly used as medicines, and can also be used for determining the binding between an integrin and a ligand, and searching for a substance capable of being bound to an integrin and a substance inhibiting the binding between an integrin and a ligand. They can also be used as diagnostic reagents.

Furthermore, it has been found that an integrin isolated with a stably associated structure can be bound to an extracellular matrix under physiological conditions and in the presence of plasma components. Thus, it has been found that an integrin or an extracellular matrix receptor can be applied as a platelet substitute.